EPLERENONE IN MYOCARDIAL INFARCTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article focuses on aldosterone antagonists application in myocardial infarction patients. The main issue here is that regardless of certain indications for prescription, the tendency is not to use this group of drugs. Among them - eplerenone, drug of choice, which showed its benefits in multicenter randomized trials, comparing to spironolactone as well. The authors give an overview of studies and discuss the pathophysiological background for the use of eplerenone in patients with myocardial infarction.

Full Text

Restricted Access

About the authors

Ivan Gennadievich Gordeev

N.I. Pirogov Russian National Research Medical University

MD, Professor, Head of the Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St

Yevgeniy Olegovich Taratukhin

N.I. Pirogov Russian National Research Medical University

PhD, Associate Professor, Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St

Yekaterina Titovna Razumova

N.I. Pirogov Russian National Research Medical University

PhD, Associate Professor, Department of Hospital Therapy № 1, Medical Faculty 117997, Moscow, 1 Ostrovityanova St

References

  1. Tanai E., Frantz S. Pathophysiology of Heart Failure. Compr. Physiol. 2016;6(1):187-214.
  2. Rocha R., Stier C.T., Kifor I., Ochoa-Maya M.R., Rennke H.G., Williams G.H., Adler G.K. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141(10):3871-8.
  3. Scabbia E.V., Scabbia L. The cardio-renal syndrome (CRS). IJC Metabolic Endocrine. 2015;9:1-4.
  4. Kritis A.A., Gouta C.P., Liaretidou E.I., Kallaras K.I. Latest aspects of aldosterone action on the heart muscle. J. Physiol. Pharmacol. 2016;67(1):21-30.
  5. Соболева В.Н., Таратухин Е.О. Антагонисты минералокортикоидов: селективность дает новые возможности терапии сердечной недостаточности. Российский кардиологический журнал. 2015;1:104-6.
  6. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003;348(14):1309-21.
  7. Zannad F., McMurray J. J. V., Drexler H., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Vincent J., Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). Eur. J. Heart Fail. 2010;12(6):617-22.
  8. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Vincent J., Pocock S.J., Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011;364(1):11-21.
  9. Struthers A.D. Pathophysiology of heart failure following myocardial infarction. Heart. 2005;91 (Suppl. 2):14-6.
  10. Palmer B.R., Pilbrow A.P., Frampton C.M., Yandle T.G., Skelton L., Nicholls M.G., Richards A.M. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur. Heart J. 2008;29(20):2489-96.
  11. Steg P.G., James S.K., Atar D., Badano L.P., Blömstrom-Lundqvist C., Borger M.A., Di Mario C., Dickstein K., Ducrocq G., Fernandez-Aviles F., Gershlick A.H., Giannuzzi P., Halvorsen S., Huber K., Juni P., Kastrati A., Knuuti J., Lenzen M.J., Mahaffey K.W., Valgimigli M., van't Hof A., Widimsky P., Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012;33(20):2569-619.
  12. Rassi A.N., Cavender M.A., Fonarow G.C., Cannon C.P., Hernandez A.F., Peterson E.D., Peacock W.F., Laskey W.K., Rosas S.E., Zhao X., Schwamm L.H., Bhatt D.L. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J. Am. Coll. Cardiol. 2013;61(1):35-40.
  13. Adamopoulos C., Ahmed A., Fay R., Angioi M., Filippatos G., Vincent J., Pitt B., Zannad F. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur. J. Heart Fail. 2009;11(11):1099-105.
  14. Beygui F., Vicaut E., Ecollan P., Machecourt J., van Belle E., Zannad F., Montalescot G. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am. Heart J. 2010;160(4):642-8.
  15. Montalescot G. ALBATROSS Trial. 2015 [cited 2016 16 May]; Available from: https://www.escardio.org/static_file/ Escardio/Press-media/Press releases/2015/Congress/montalescot-albaross.pdf.
  16. Rossignol P., Cleland J.G.F., Bhandari S., Tala S., Gustafsson F., Fay R., Lamiral Z., Dobre D., Pitt B., Zannad F. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study. Circulation. 2012;125(2):271-9.
  17. O'Keefe J.H., Abuissa H., Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes. Metab. 2008;10(6):492-7.
  18. Pitt B., Bakris G., Ruilope L.M., DiCarlo L., Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118(16):1643-50.
  19. Le H.H., El-Khatib C., Mombled M., Guitarian F., Al-Gobari M., Fall M., Janiaud P., Marchant I., Cucherat M., Bejan-Angoulvant T., Gueyffier F. Impact of aldosterone antagonists on sudden cardiac death prevention in heart failure and post-myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials. Plos One. 2016;11(2):e0145958.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies